prikaz prve stranice dokumenta Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
  Preuzmi
PDF 1.32 MB
Znanstveni rad - Ostalo
Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
Angiology, 71 (2019), 2; 105-107. https://doi.org/10.1177/0003319719855165
Reiner, Željko; Sirtori, Cesare R.; Banach, Maciej; Ruscica, Massimiliano; Sahebkar, Amirhossein

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Reiner, Ž., Sirtori, C. R., Banach, M., Ruscica, M. i Sahebkar, A. (2019). Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. Angiology, 71. (2), 105-107. doi: 10.1177/0003319719855165

Reiner, Željko, et al. "Methotrexate for Cardiovascular Risk Reduction: The Right Choice?." Angiology, vol. 71, br. 2, 2019, str. 105-107. https://doi.org/10.1177/0003319719855165

Reiner, Željko, Cesare R. Sirtori, Maciej Banach, Massimiliano Ruscica i Amirhossein Sahebkar. "Methotrexate for Cardiovascular Risk Reduction: The Right Choice?." Angiology 71, br. 2 (2019): 105-107. https://doi.org/10.1177/0003319719855165

Reiner, Ž., et al. (2019) 'Methotrexate for Cardiovascular Risk Reduction: The Right Choice?', Angiology, 71(2), str. 105-107. doi: 10.1177/0003319719855165

Reiner Ž, Sirtori CR, Banach M, Ruscica M, Sahebkar A. Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. Angiology [Internet]. 2019. [pristupljeno 11.05.2024.];71(2):105-107. doi: 10.1177/0003319719855165

Ž. Reiner, C. R. Sirtori, M. Banach, M. Ruscica i A. Sahebkar, "Methotrexate for Cardiovascular Risk Reduction: The Right Choice?", Angiology, vol. 71, br. 2, str. 105-107, 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:635602. [Citirano: 11.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:635602
Podaci o radu
Naslov (engleski)Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
AutorŽeljko Reiner
AutorCesare R. Sirtori
AutorMaciej Banach
AutorMassimiliano Ruscica
AutorAmirhossein Sahebkar
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
The causative role of inflammation in atherosclerosis and cardiovascular (CV) disease (CVD) has been well established.1 Rheumatoid arthritis (RA), a condition associated with systemic inflammation, is included in the CVD risk calculation provided by an analysis of the national QRESEARCH database that included 2.3 million people.2 Furthermore, in clinical practice, the most recent European guidelines clearly state that RA enhances CVD risk independent of traditional risk factors, with a risk ratio of 1.4 and 1.5 for men and women, respectively.3 Thus, there is now considerable evidence supporting that CVD incidence is increased by about 50% in patients with RA and that one of the leading causes of increased mortality in these patients is early CVD caused by accelerated atherogenesis.4 Therefore, the Cardiovascular Inflammation Reduction Trial (CIRT) trial aimed to assess the effect of inhibiting inflammation with low-dose methotrexate (vs placebo) on the rate of CV events in coronary patients with either type 2 diabetes or metabolic syndrome
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Ostalo
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAngiology
Brojčani podacivol. 71, br. 2, str. 105-107
p-ISSN0003-3197
DOIhttps://doi.org/10.1177/0003319719855165
URN:NBNurn:nbn:hr:184:635602
Datum objave publikacije2019
URL dokumentahttp://bib.irb.hr/1106866
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-18 12:56:40